How Did James Bond Spark a 50-Year Legal War Over Who Owns 007? — No Infringement Intended Podcast
Episode 406 -- AI Risks and Compliance: Building a Governance Framework
The Briefing: Taylor Swift, Trademark Law, and the Fight Over ‘Life of a Showgirl’
DOJ’s Bulk Sensitive Data Transfer Rule: Key Insights for Health Care Compliance Teams – Diagnosing Health Care
SBR-Author’s Podcast: Bribery Beyond Borders: The Hidden History and Future of the FCPA with Severin Wirz
'Urgent National Action to Save College Sports': Trump’s NIL Playbook — Highway to NIL Podcast
March Madness or Trademark Madness? The NCAA v. DraftKings Lawsuit
Protecting Your Products and Brand Online
Lemon Pound Cake and the First Amendment
Episode 402: Paul Allen: The Promise of AI, Governance and Public Trust
Michele Moresco on the Transformational Potential of Photonics
Subject Matter Eligibility Challenges in Post-Grant Proceedings — Patents: Post-Grant Podcast
The Briefing: Vampires, Love Triangles, but No Infringement
Non-Competes in 2026: FTC Signals Major Policy Shift - Employment Law This Week® - Spilling Secrets Podcast
When Does a Beat Make You a Co-Writer? — No Infringement Intended Podcast
The Briefing: The Sound of a Lawsuit – David Greene vs Google NotebookLM
JONES DAY PRESENTS®: Trade Secret Litigation 10 Years After Enactment of the Defend Trade Secrets Act
JONES DAY TALKS®: Women in IP – Supreme Court Denies Review of Thaler v. Perlmutter: AI Authorship Questions Remain
The Briefing: No Paper, No Standing: Kanye West, Copyright Transfers, and the Writing Requirement
The Briefing: Skechers, TikTok, and Khaby Lame: Is Barrett Wissman Potentially Liable?
Part 1: Due Diligence and - Opinions This is the first article in a four-part series examining how AI is reshaping patent strategy across the lifecycle of life sciences assets—from diligence and prosecution to...more
Artificial intelligence (AI) has become nearly ubiquitous in everyday life, and given AI’s widespread use across industries, it is no surprise that the United States Patent and Trademark Office (USPTO) has taken a keen...more
Under 35 USC § 303(a), the US Patent and Trademark Office (USPTO) must determine within three months of the filing of a reexamination request whether the request raises a substantial new question of patentability....more
The U.S. Patent and Trademark Office has extended its Artificial Intelligence Search Automated Pilot Program (ASAP!) until June 1, 2026. Originally slated to close to new petitions on April 20, 2026 (see “USPTO Announces...more
The Federal Circuit reversed a District Court grant of judgment as a matter of law (JMOL) that overturned a jury verdict that defendant Eli Lilly had not satisfied the clear-and-convincing-evidence standard in challenging on...more
In Trustees Of Columbia University v. Gen Digital Inc., Appeal No. 24-1243, the Federal Circuit held that software claims were directed to an abstract idea at Alice step one where the technical improvements described in the...more
On April 9, 2026, Hybron Technologies (“Hybron”) announced the closing of an oversubscribed $25M seed round. Hybron is a manufacturing company that develops lightweight composites for aerospace and defense applications. The...more
On April 2, 2026, the Nuclear Regulatory Commission (NRC) proposed a rule to streamline commercial licensing of reactor designs already authorized by the Department of Energy (DOE) or Department of Defense (DOD), as reported...more
Business divorce cases are most often litigated in state courts, and that can create difficulty for all those involved. Based on anecdotal evidence (me talking with members of the judiciary at various lawyer events), many...more
Texas House Bill 40, passed last summer and effective as of September 1, 2025, significantly expanded the jurisdiction of the Texas Business Court – the specialized courts launched in September 2024 to handle high-stakes...more
The Federal Circuit’s decision in Teva Pharmaceuticals v. Eli Lilly & Co. (Appeal No. 24-1094) clarifies how Patent Act Section 112’s written description and enablement requirements apply to methods of using antibodies....more
In this episode of No Infringement Intended, Austin Padgett and Rusty Close unpack the half-century battle over who really owns James Bond. They trace how Ian Fleming's early collaborations fractured the rights to Thunderball...more
Artificial intelligence is rapidly transforming business operations—but it is also introducing a new generation of legal, ethical, and compliance risks. In this episode, we explore how AI risk is accelerating across...more
Can a five word phrase be worth millions? In this episode of The Briefing, Weintraub Tobin partners Scott Hervey and Matt Sugarman break down the high stakes trademark dispute between Las Vegas performer Maren Flagg and...more
A series of lawsuits highlights mounting scrutiny over AI safety and accountability. A federal suit in the Northern District of California accuses xAI of knowingly allowing its Grok chatbot to generate child sexual abuse...more
Over the past year, the U.S. Department of Justice’s (DOJ) Antitrust Division has delivered consistent message about the relationship between antitrust law and intellectual property (IP) rights: strong patent rights and...more
Few brands have matched the impact Rolex has had on the evolution of horology. From the 1926 debut of the “Oyster,”[1] the world’s first waterproof case, to the perfection of the “perpetual self-winding rotor”[2] in 1931,...more
Fortress Iron, LP v. Digger Specialties, Inc., 2026 WL 899158 (Fed. Cir. April 2, 2026) - The Constitution mandates that the U.S. patent system promote the progress of science and useful arts. Naming and crediting all...more
Today the Federal Circuit reversed a district court’s JMOL and held that claims to a method of treating headaches using a genus of antagonistic anti-CGRP antibodies satisfied both the written description and enablement...more
Pegfilgrastim Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple...more
This chart summarizes the case name, drug, patents-in-suit, and publicly available terms for reported settlements in federal district court cases that are filed pursuant to the Hatch-Waxman Act....more
*Etanercept Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple...more
Tocilizumab Challenged Claim Types in IPRs: Claims are counted in each IPR, so claims from the same patent challenged in multiple IPRs are counted more than once. Within each IPR, claims are counted only once, whether they...more
From 1 April 2026, Vietnam's amended Intellectual Property Law significantly accelerates IP examination, opposition and registration timelines, while introducing new fast‑track options for qualifying applications. Although...more
Denosumab Challenged Claim Types in Litigation: Claims are counted in each litigation, so claims from the same patent challenged in multiple litigations are counted more than once. Within each litigation a claim is counted...more